A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 500 shares of PRPH stock, worth $1,135. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 2,400 79.17%
Holding current value
$1,135
Previous $15,000 86.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.18 - $7.35 $12,435 - $21,866
-2,975 Reduced 43.92%
3,798 $15,000
Q1 2024

May 15, 2024

BUY
$4.47 - $6.47 $30,275 - $43,821
6,773 New
6,773 $43,000
Q3 2023

Nov 14, 2023

BUY
$4.23 - $7.53 $11,577 - $20,609
2,737 Added 511.59%
3,272 $14,000
Q2 2023

Aug 14, 2023

SELL
$7.15 - $9.78 $173,852 - $237,800
-24,315 Reduced 97.85%
535 $3,000
Q1 2023

May 15, 2023

BUY
$6.62 - $9.57 $92,388 - $133,558
13,956 Added 128.11%
24,850 $189,000
Q4 2022

Feb 14, 2023

BUY
$8.78 - $12.47 $95,649 - $135,848
10,894 New
10,894 $104,000
Q1 2022

May 16, 2022

SELL
$6.2 - $7.87 $65,242 - $82,816
-10,523 Reduced 36.99%
17,926 $125,000
Q4 2021

Feb 14, 2022

BUY
$5.13 - $7.89 $34,319 - $52,784
6,690 Added 30.75%
28,449 $203,000
Q3 2021

Nov 15, 2021

BUY
$4.89 - $7.82 $28,831 - $46,106
5,896 Added 37.17%
21,759 $113,000
Q2 2021

Aug 16, 2021

SELL
$4.61 - $6.83 $27,701 - $41,041
-6,009 Reduced 27.47%
15,863 $98,000
Q1 2021

May 17, 2021

BUY
$6.19 - $16.0 $135,387 - $349,952
21,872 New
21,872 $162,000
Q2 2019

Aug 14, 2019

SELL
$2.1 - $3.07 $36,930 - $53,989
-17,586 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$2.7 - $3.65 $16,310 - $22,049
6,041 Added 52.33%
17,586 $0
Q1 2018

May 11, 2018

SELL
$2.24 - $3.21 $618 - $885
-276 Reduced 2.33%
11,545 $34,000
Q4 2017

Feb 09, 2018

BUY
$2.05 - $2.3 $24,233 - $27,188
11,821
11,821 $26,000

Others Institutions Holding PRPH

About ProPhase Labs, Inc.


  • Ticker PRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 16,024,400
  • Market Cap $36.4M
  • Description
  • ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...
More about PRPH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.